Cargando…

ANXA6: a key molecular player in cancer progression and drug resistance

Annexin-A6 (ANXA6), a Ca(2+)-dependent membrane binding protein, is the largest of all conserved annexin families and highly expressed in the plasma membrane and endosomal compartments. As a multifunctional scaffold protein, ANXA6 can interact with phospholipid membranes and various signaling protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jinlong, Wan, Shun, Chen, Siyu, Yang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154440/
https://www.ncbi.nlm.nih.gov/pubmed/37129645
http://dx.doi.org/10.1007/s12672-023-00662-x
_version_ 1785036124120416256
author Cao, Jinlong
Wan, Shun
Chen, Siyu
Yang, Li
author_facet Cao, Jinlong
Wan, Shun
Chen, Siyu
Yang, Li
author_sort Cao, Jinlong
collection PubMed
description Annexin-A6 (ANXA6), a Ca(2+)-dependent membrane binding protein, is the largest of all conserved annexin families and highly expressed in the plasma membrane and endosomal compartments. As a multifunctional scaffold protein, ANXA6 can interact with phospholipid membranes and various signaling proteins. These properties enable ANXA6 to participate in signal transduction, cholesterol homeostasis, intracellular/extracellular membrane transport, and repair of membrane domains, etc. Many studies have demonstrated that the expression of ANXA6 is consistently altered during tumor formation and progression. ANXA6 is currently known to mediate different patterns of tumor progression in different cancer types through multiple cancer-type specific mechanisms. ANXA6 is a potentially valuable marker in the diagnosis, progression, and treatment strategy of various cancers. This review mainly summarizes recent findings on the mechanism of tumor formation, development, and drug resistance of ANXA6. The contents reviewed herein may expand researchers’ understanding of ANXA6 and contribute to developing ANXA6-based diagnostic and therapeutic strategies.
format Online
Article
Text
id pubmed-10154440
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-101544402023-05-04 ANXA6: a key molecular player in cancer progression and drug resistance Cao, Jinlong Wan, Shun Chen, Siyu Yang, Li Discov Oncol Review Annexin-A6 (ANXA6), a Ca(2+)-dependent membrane binding protein, is the largest of all conserved annexin families and highly expressed in the plasma membrane and endosomal compartments. As a multifunctional scaffold protein, ANXA6 can interact with phospholipid membranes and various signaling proteins. These properties enable ANXA6 to participate in signal transduction, cholesterol homeostasis, intracellular/extracellular membrane transport, and repair of membrane domains, etc. Many studies have demonstrated that the expression of ANXA6 is consistently altered during tumor formation and progression. ANXA6 is currently known to mediate different patterns of tumor progression in different cancer types through multiple cancer-type specific mechanisms. ANXA6 is a potentially valuable marker in the diagnosis, progression, and treatment strategy of various cancers. This review mainly summarizes recent findings on the mechanism of tumor formation, development, and drug resistance of ANXA6. The contents reviewed herein may expand researchers’ understanding of ANXA6 and contribute to developing ANXA6-based diagnostic and therapeutic strategies. Springer US 2023-05-02 /pmc/articles/PMC10154440/ /pubmed/37129645 http://dx.doi.org/10.1007/s12672-023-00662-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Cao, Jinlong
Wan, Shun
Chen, Siyu
Yang, Li
ANXA6: a key molecular player in cancer progression and drug resistance
title ANXA6: a key molecular player in cancer progression and drug resistance
title_full ANXA6: a key molecular player in cancer progression and drug resistance
title_fullStr ANXA6: a key molecular player in cancer progression and drug resistance
title_full_unstemmed ANXA6: a key molecular player in cancer progression and drug resistance
title_short ANXA6: a key molecular player in cancer progression and drug resistance
title_sort anxa6: a key molecular player in cancer progression and drug resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154440/
https://www.ncbi.nlm.nih.gov/pubmed/37129645
http://dx.doi.org/10.1007/s12672-023-00662-x
work_keys_str_mv AT caojinlong anxa6akeymolecularplayerincancerprogressionanddrugresistance
AT wanshun anxa6akeymolecularplayerincancerprogressionanddrugresistance
AT chensiyu anxa6akeymolecularplayerincancerprogressionanddrugresistance
AT yangli anxa6akeymolecularplayerincancerprogressionanddrugresistance